This site is for New Zealand healthcare professionals. If you are a patient, please click here.

Please enter your email address to view the content of this website.

Not a member? Register
You are here: Home / Our Medicines

What are our core medicines?

They target HER2, CD20, VEGF, BRAF, IL6, the hedgehog pathway and lung fibrosis.

Explore below everything you need to know: booklets and forms, efficacy and safety information and useful resources.
For a full list of our products visit roche.co.nz

actemra.jpg

Actemra is an anti-IL6 receptor antibody for rheumatoid arthritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis.

avastin.jpg

Avastin is a VEGF inhibitor used to treat a wide range of cancers.

erivedge.jpg

Erivedge is a hedgehog pathway inhibitor for adults with advanced basal cell carcinoma.

esbrit.jpg

Esbriet is an oral medicine for patients with idiopathic pulmonary fibrosis (IPF)

gazyva.jpg

GAZYVA is an anti-CD20 therapy for first line chronic lymphocytic leukaemia.

herceptin.jpg

Herceptin targets HER2 in early and metastatic breast cancer, as well as gastric cancer.

kadcyla.jpg

Kadcyla is an antibody-drug conjugate for HER2-positive metastatic breast cancer.

mabthera_ra.jpg

MabThera is an anti-CD20 therapy for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

mabthera.jpg

MabThera targets the CD20 antigen to treat non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Ocrevus_Logo.jpg

OCREVUS is a monoclonal antibody that selectively targets CD20-expressing B-cells in Multiple Sclerosis

perjeta.jpg

Perjeta is a HER2 dimerisation inhibitor for neoadjuvant (eBC) and advanced breast cancer.

zelboraf.jpg

Zelboraf is a BRAF kinase inhibitor for metastatic melanoma.